New England Journal of Medicine· 2015Q1

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl et al.

1,899citations
Q1SCImago
2015year

Short summary

Venetoclax, a BCL2 inhibitor, achieved a 79% response rate in relapsed or refractory CLL/SLL patients, including 20% complete remissions, in a phase 1 trial.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine